Work

Escort aptamers: a delivery service for diagnosis and therapy

Year: 2000
Type: article
Abstract: In 1990, the discovery of aptamers by Tuerk and Gold (1) and subsequently by Ellington and Szostak (2) spawned significant interest within academia and industry.Aptamers have quickly become valuable research tools (3-5).More than that, a therapeutic aptamer (6) has entered clinical evaluation just eight years after the inception of the technology.While aptamers have built inroads into therapeutic applications, they may also become important in vitro diagnostic tools (7).Here, we discuss a new development: the use of "escort aptamers" as targeting agents for in vivo diagnosis and therapy.Instead of directly interrupting a disease process, as would a function-blocking aptamer, escort aptamers are designed to deliver radionuclides, toxins, or cytotoxic agents to diseased tissue.Specifically, we focus on the delivery of benign radionuclides for in vivo diagnosis of disease.For discussion of function-blocking aptamers, see White et al., this Perspective series (8). Aptamers and antibodiesThe advent of monoclonal antibodies in 1974 brought to mind Paul Ehrlich's turn-of-the-century insight that molecules could serve as "magic bullets" that home to pathological organisms with precision (http://nobel.sdsc.edu/medicine/laureates/1908/ehrlich-bio.html).Indeed, the high affinity and specificity of antibodies provide some of the key properties in Ehrlich's concept.Despite some successes in tissue targeting, antibodies are saddled with a fundamental disadvantage: their large size (∼155 kDa) results in slow tissue penetration and long blood residence.For example, in clinical settings where an antibody is coupled to a cellkilling radionuclide, this long circulation half-life leads to bone marrow toxicity that limits the permissible dose (9).To decrease blood half-life while maintaining target specificity, a second generation of smaller antibody fragments has been designed (10,11).Antibody pretargeting strategies also show promise (12-14), and small peptides can have excellent pharmacokinetic profiles (15).However, many approaches are limited by complexity of clinical protocols, paucity of available targeting molecules, low-
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2071745634
FWCI: 5.451
Cites: 29
Cited by: 171
Related to: 9